Get Started

NRSN

NASD Neurosense Therapeutics Ltd.
Nov 3, 2026 · 12:45 PM ET DELAYED Market Open

$1.37 ↓ -0.06 (-4.20%) Trading Down from the previous close of $1.43, $0.09 below the day’s high of $1.46

YTD change
-91.09%
vs 20-day SMA
-51.53%
vs 200-day SMA
-89.28%

Price ranges

Previous day
$1.10 $2.04
open $2.02 close $1.43
-$0.59 (-29.21%)
Today
$1.33 $1.46
open $1.40 now $1.37
-$0.03 (-2.14%)
Past week
$1.10 $2.60
from $2.33 now $1.37
-$0.96 (-41.20%)
Past month
$1.10 $4.33
from $4.03 now $1.37
-$2.66 (-66.00%)
This year
$0.25 $15.38
from $15.38 now $1.37
-$14.01 (-91.09%)

Price & Performance

+0.54 (+60.67%) / 6M

$-0.2334$2.50$5.23$7.97May 4Aug 4Nov 2

Signals & Sentiment

Momentum, market sentiment, and recent alerts

Poor
  • The stock is 99.2% away from all-time highs of $163.60
  • NRSN is down 91% since the beginning of the year
  • NRSN is down 94% over the past 12 months
  • NRSN is down 66% over the past 1 month
  • 2% of all NRSN investors are betting against NRSN

NRSN reads poor: price sits below both the 20- and 200-day averages, the 12-month move is +32.4%.

Financial Strength

Earnings, valuation, and balance sheet

Earnings

Profitable No
EPS $-2.06
Earnings momentum N/A Quarterly EPS growth
Quarterly change N/A

Valuation

P/E ratio N/A
Enterprise value $1.8M
Beta 5.17

Balance sheet & scale

IncomeN/A
RevenueN/A
Cash$213.0K
Debt$170.0
Income / Debt N/A

Company & Peers

Company profile and competitor comparison

Company profile

ExchangeNASD
Sector Professional, Scientific, and Technical Services
Industry Group Scientific Research and Development Services
Market cap $2.6M

Neurosense Therapeutics Ltd. is a clinical-stage biotechnology company, which engages n the discovery and development of targeted therapeutics for neurodegenerative diseases. The firm offers PrimeC, a therapy for amyotrophic lateral sclerosis (ALS). It also conducts testing of product candidates for the treatment of Parkinson's and Alzheimer's diseases. The company was founded by Alon Ben-Noon on February 13, 2017 and is headquartered in Herzliya, Israel.

Competitor comparison

TickerCompany PriceChange
REGN Regeneron Pharmaceuticals, Inc. $961.26 +3.60%
IQV IQVIA Holdings Inc $258.44 -3.33%
CRL Charles River Laboratories International, Inc. $338.54 -5.81%
ICLR ICON Plc $205.14 -2.94%
IT Gartner, Inc. $235.26 +2.83%

You looked up one stock
Trade Ideas watches them all

Real-time scanning and AI-generated signals across the entire market.

See plans TI Pro Download

Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.